SLAS Discovery Guest Editors Sarine Markossian, Ph.D., Matthew D Hall, Ph.D., G. Sitta Sittampalam, Ph.D., Jayme Dahlin, M.D., Ph.D. and Nathan P. Coussens, Ph.D. invite the submission of abstracts for the Assay Guidance Manual for Drug Discovery: Robust or Go Bust for publication in a 2021 Special Issue. The abstracts will be used to select and invite papers for review and publication consideration.
The Guest Editors seek high-quality, short- or full-length research reports, reviews and perspectives related to the Assay Guidance Workshop for High-Throughput Screening and Lead Discovery. It is recommended that submissions contain specific novel examples and/or new case studies that will reinforce best practices in assay development exemplified by the Assay Guidance Manual (AGM).
Development, optimization and implementation of in vitro biochemical, biophysical and cell-based assays
Statistical design of experiments for assay development
Concepts, guidelines and best-practices for robust biochemical and cell-based assays
Biophysical methods for small molecule discovery and validation
Kinetics of target binding: kinetic artifacts in potency assays and methods for measuring binding kinetics
The application of stem cells in drug discovery
Predictive strategies for drug-induced liver injury (DILI)
Assay development for high-content screening and best practices
Approaches for multi-parametric phenotypic high-throughput screening
Data analysis for high-content screening
Artificial intelligence (AI) and machine learning (ML) in high-content screening
Assays for lead optimization
Lead selection and optimization by medicinal chemistry
Survey of assay technologies for HTS and lead optimization
Mass spectrometry for drug screening and lead optimization
Biophysical methods for lead optimization
Assays and concepts to identify and mitigate sources of artifacts and interferences
Common bioassay interference mechanisms including aggregation and chemical reactivity
Strategies to design small molecule discovery assays and counter screens to enrich hits with genuine biological activity
Common sources of assay artifacts from instrumentation
Optimal selection of instrumentation, reagents and assay technologies to reduce assay interferences
Assay validation, operations, quality control and data analysis
Assay operations: planning for robust assays
Microplate selection and recommended practices in high-throughput screening and quantitative biology
Basic assay statistics, data analysis and rules of thumb
Reproducibility, comparison and correlation of in vitro assays
Reproducibility and differentiability in potency assays
Best practices in compound management
Pharmacokinetics and drug metabolism
In vitro assessment of ADME properties of lead compounds
ADME assay optimization
Use of complex in vitro models (CIVMs) in preclinical drug discovery
The emergence of CIVMs in disease modeling
The emergence of CIVMs in safety testing
Submit your manuscript proposalbefore October 1, 2020. Submissions should include your name, contact information, affiliation, a working title and abstract (250-500 words) as an MS Word document.
Invited manuscripts will need to be completed and submitted by February 1, 2021. All submitted papers will be subject to peer-review to ensure scientific rigor, clarity of expression and integration with other contributions in the SLAS Discovery Special Issue.
Publication note: After submissions are accepted, they typically publish online ahead-of-print within 30 days and become immediately searchable and citable with a DOI.